Lates News

Lilly Corporation (LLY) fell 2.2% in early trading on Thursday. It was reported earlier that the company had stopped a experimental drug study aimed at preventing excessive muscle loss in obese patients for strategic business considerations. Additionally, Lilly also plans to launch its experimental weight loss drug orforpligron in India.